Comprehensive Clinical Guide: Mycotic Aneurysm (Infected Aneurysm)

1. Introduction and Clinical Overview

A mycotic aneurysm—despite the etymological implication of fungal involvement—is clinically defined as an infected aneurysm of an artery, most commonly caused by bacterial pathogens. The term was coined by Sir William Osler in 1885, describing an aneurysm resulting from an embolus derived from bacterial endocarditis. While the name suggests a fungal etiology, the vast majority of cases are secondary to Staphylococcus aureus, Salmonella species, or Streptococcus species.

These lesions represent a surgical emergency. Unlike atherosclerotic aneurysms, which are typically degenerative and slowly progressive, mycotic aneurysms are characterized by rapid expansion, high risk of spontaneous rupture, and significant systemic inflammatory response. They are true aneurysms (involving all three layers of the arterial wall) or pseudoaneurysms that develop due to microbial destruction of the arterial wall integrity.

2. Etiology and Pathophysiology

The development of a mycotic aneurysm is a multi-step process involving the seeding of the arterial wall and subsequent structural failure.

Pathogenetic Mechanisms

• Hematogenous Seeding: Bacteria enter the bloodstream (bacteremia) and adhere to the vasa vasorum or an existing atherosclerotic plaque.
• Direct Extension: Infection from adjacent soft tissue or bone (e.g., osteomyelitis or septic arthritis) erodes into the arterial wall.
• Contamination: Iatrogenic injury during endovascular procedures or intravenous drug use (IVDU).
• Septic Embolization: Fragments of infected heart valves (endocarditis) break off and lodge in distal arteries, causing localized vessel wall inflammation and focal dilation.

The Microbiological Profile

Pathophysiological Progression

1. Vascular Seeding: Microorganisms colonize the intima.
2. Inflammatory Cascade: Infiltration of neutrophils and macrophages releases proteases (MMPs) that degrade the internal elastic lamina.
3. Wall Weakening: The arterial media is destroyed, leading to eccentric dilation.
4. Rupture: Rapid wall thinning leads to catastrophic hemorrhage.

3. Clinical Presentation and Staging

Standard Presentation

The classic triad of a mycotic aneurysm includes:
1. Fever/Systemic Toxicity: Unexplained pyrexia, malaise, and rigors.
2. Localized Pain: Pulsatile mass accompanied by severe, focal tenderness.
3. Bacteremia: Positive blood cultures in 50–80% of patients.

Anatomical Distribution

• Aorta (Abdominal/Thoracic): Highest mortality.
• Femoral Artery: Common in IVDU.
• Visceral Arteries: Superior mesenteric or renal artery involvement.
• Intracranial: Often associated with subacute bacterial endocarditis.

Grading/Staging (Clinical Severity)

While there is no universally standardized "TNM" system for mycotic aneurysms, clinicians typically grade them based on the Chahwan Classification:
* Grade I: Early/Incidental finding, minimal wall change.
* Grade II: Established aneurysm with local inflammation.
* Grade III: Ruptured or contained rupture with systemic sepsis.

4. Diagnostic Workup and Imaging

A definitive diagnosis requires high-resolution imaging and microbiological confirmation.

Key Diagnostic Tests

• Computed Tomography Angiography (CTA): The gold standard. Look for eccentric morphology, perianeurysmal fat stranding, fluid collections, or gas bubbles in the vessel wall.
• Blood Cultures: Must be obtained before antibiotic administration. Three sets are standard.
• Echocardiography (TTE/TEE): Essential to rule out infective endocarditis as the primary source of emboli.
• PET/CT: Increasingly utilized to detect subclinical infection or occult sites of sepsis (e.g., spondylodiscitis).

Differential Diagnosis

It is critical to distinguish mycotic aneurysms from:
* Atherosclerotic Aneurysm: Generally fusiform, lacks perianeurysmal inflammation.
* Vasculitis (e.g., Takayasu, Giant Cell): Usually presents with wall thickening rather than focal dilation.
* Arterial Dissection: Characterized by an intimal flap.
* Tumor-related pseudoaneurysm: Malignancy invading the vessel wall.

5. Management and Therapeutic Strategy

Treatment must be aggressive and multidisciplinary, involving vascular surgery, infectious disease specialists, and interventional radiology.

Medical Management

• Intravenous Antibiotics: Broad-spectrum coverage initiated immediately after cultures, then de-escalated based on sensitivity.
• Duration: Usually 6 weeks of IV therapy, followed by long-term oral suppression if the source remains.

Surgical/Endovascular Options

• Open Surgical Repair: The gold standard. Involves resection of the infected segment, thorough debridement of surrounding infected tissue, and extra-anatomic bypass (bypassing the infected field).
• Endovascular Repair (EVAR/TEVAR): Increasingly used in high-risk patients. Controversial due to the risk of "stent-graft infection," but often necessary for unstable patients.

6. Risks, Side Effects, and Contraindications

Managing mycotic aneurysms carries significant risks:
* Graft Infection: High risk of reinfection if a prosthetic graft is placed in a contaminated field.
* Multi-Organ Failure: Secondary to systemic sepsis.
* Rupture: The most feared complication, often leading to exsanguination.
* Contraindications for Endovascular Repair: Extensive periaortic abscess or high-grade infection that precludes the placement of a foreign body (stent-graft).

7. Frequently Asked Questions (FAQ)

1. Is a mycotic aneurysm always caused by fungus?

No. The term is a historical misnomer. Most are bacterial in origin.

2. How fast do these aneurysms grow?

Extremely rapidly. Unlike atherosclerotic aneurysms that grow over years, mycotic aneurysms can expand and rupture in days or weeks.

3. What is the role of PET/CT?

PET/CT is highly sensitive for detecting metabolic activity (inflammation) and is useful for identifying the primary source of infection in the body.

4. Can you treat a mycotic aneurysm with antibiotics alone?

Rarely. While antibiotics are mandatory, they are usually insufficient to resolve the structural weakness of the arterial wall. Surgery is almost always required.

5. Why is the mortality rate so high?

Mortality remains high (20–40%) due to the combination of severe sepsis and the technical difficulty of operating in an infected surgical field.

6. What is the most common site for a mycotic aneurysm?

The abdominal aorta is the most common site for atherosclerotic-related mycotic aneurysms, while the femoral artery is common in intravenous drug users.

7. How are blood cultures managed if the patient is already on antibiotics?

If the patient is already on antibiotics, specialized media or "antibiotic removal devices" may be used, though sensitivity is significantly reduced.

8. What is an extra-anatomic bypass?

It is a surgical technique where the blood flow is routed away from the infected site (e.g., axillobifemoral bypass) to avoid placing a graft through an abscess.

9. Are there long-term complications?

Yes. Patients require lifelong surveillance for recurrent infection, graft failure, or the development of secondary aneurysms.

10. Can these aneurysms be prevented?

Prevention focuses on the prompt treatment of bacteremia, endocarditis, and avoiding the reuse of non-sterile needles in IV drug use.

8. Prognosis and Long-term Surveillance

The prognosis for a mycotic aneurysm is guarded. Success is dependent on the speed of diagnosis and the efficacy of source control. Even after successful surgery, patients require:
* Serial Imaging: CTA at 3, 6, and 12 months post-operatively.
* Infectious Disease Follow-up: Monitoring inflammatory markers (CRP/ESR).
* Lifestyle Modification: Specifically for IVDU patients, where recurrence is high if the behavior persists.

Prognostic Indicators

This guide serves as a foundational reference for clinicians. Given the rapid progression of mycotic aneurysms, a high index of suspicion is required in any patient presenting with fever, localized arterial pain, and a history of bacteremia or risk factors for vascular infection. Early referral to a tertiary vascular center is the single most important action in improving patient outcomes.

Disclaimer: This guide is for educational purposes for healthcare professionals and does not constitute formal medical advice. Clinical decisions should be based on institutional protocols and individual patient assessment.